AR059183A1 - Uso de derivados de 2- imidazol o imidazolina sustituidos para preparar medicamentos - Google Patents
Uso de derivados de 2- imidazol o imidazolina sustituidos para preparar medicamentosInfo
- Publication number
- AR059183A1 AR059183A1 ARP070100322A ARP070100322A AR059183A1 AR 059183 A1 AR059183 A1 AR 059183A1 AR P070100322 A ARP070100322 A AR P070100322A AR P070100322 A ARP070100322 A AR P070100322A AR 059183 A1 AR059183 A1 AR 059183A1
- Authority
- AR
- Argentina
- Prior art keywords
- disorders
- benzofuran
- halogen
- phenyl
- lower alkyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical group C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 title 1
- -1 hydroxy, amino Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 208000030814 Eating disease Diseases 0.000 abstract 2
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 235000014632 disordered eating Nutrition 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000017164 Chronobiology disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- XCUAIINAJCDIPM-XVFCMESISA-N N(4)-hydroxycytidine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=NO)C=C1 XCUAIINAJCDIPM-XVFCMESISA-N 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 125000004532 benzofuran-3-yl group Chemical group O1C=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 230000036760 body temperature Effects 0.000 abstract 1
- 230000027288 circadian rhythm Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000013632 homeostatic process Effects 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000007257 malfunction Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 229910052722 tritium Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere al uso de compuestos formula (1) en la que R es hidrogeno, tritio, hidroxi, amino, alquilo inferior, cicloalquilo, alcoxi inferior, halogeno, ciano, alquilo inferior sustituido por halogeno, alcoxi inferior sustituido por halogeno, fenilo, -O-fenilo, -S-fenilo, opcionalmente sustituido por halogeno o es bencilo, benciloxi, NHC(O)-alquilo inferior o piridin-2-, -3- o -4-ilo; R1 es hidrogeno, hidroxi o alquilo inferior; R2 es hidrogeno o alquilo inferior; arilo es un resto aromático, elegido entre fenilo, naftalen1-ilo o naftalen-2-ilo; heteroarilo es un resto aromático, que contiene por lo menos un átomo de O, N o S, elegido entre el grupo formado por piridin-3-ilo, pirazolilo, benzofuran-3-ilo, benzofuran-4- ilo, benzofuran-5-ilo, benzofuran-6-ilo, benzofuran-7-ilo, tiofen-2-ilo, tiofen-3-ilo, benzo[b]tiofen-3-ilo y indol-3-ilo; n es 1, 2, 3, 4 o 5 cuando n es 2, 3, 4 o 5, R puede ser el mismo o no; la línea. de puntos puede ser un enlace o no; y a sus sales farmacéuticamente activas para la fabricacion de medicamentos destinados al tratamiento de la depresion, trastornos de ansiedad, trastorno bipolar, trastorno de hiperactividad con déficit de atencion, trastornos relacionados con el estrés, trastornos sicoticos, por ejemplo esquizofrenia, enfermedades neurologicas, por ejemplo la enfermedad de Parkinson, trastornos neurodegenerativos por ejemplo la enfermedad de Alzheimer, epilepsia; migrana, hipertension, abuso de fármacos y trastornos metabolicos, por ejemplo trastornos de ingestion de comida, diabetes, complicaciones diabéticas, obesidad, dislipidemia, trastornos de consuno y asimilacion de energía, trastornos y malfuncion de la temperatura corporal; homeostasis, trastornos de sueno y ritmo circadiano, y trastornos cardiovasculares.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06100955 | 2006-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059183A1 true AR059183A1 (es) | 2008-03-12 |
Family
ID=38226290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070100322A AR059183A1 (es) | 2006-01-27 | 2007-01-25 | Uso de derivados de 2- imidazol o imidazolina sustituidos para preparar medicamentos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7875645B2 (es) |
| EP (1) | EP1981497A2 (es) |
| JP (1) | JP2009524617A (es) |
| KR (1) | KR20080080410A (es) |
| CN (1) | CN101374516A (es) |
| AR (1) | AR059183A1 (es) |
| AU (1) | AU2007209381A1 (es) |
| BR (1) | BRPI0707315A2 (es) |
| CA (1) | CA2637312A1 (es) |
| IL (1) | IL192884A0 (es) |
| NO (1) | NO20083369L (es) |
| RU (1) | RU2008130455A (es) |
| TW (1) | TW200738233A (es) |
| WO (1) | WO2007085557A2 (es) |
| ZA (1) | ZA200806456B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7592362B2 (en) * | 2006-01-19 | 2009-09-22 | Pfizer Limited | Substituted imidazoles |
| CN101600700B (zh) | 2007-02-02 | 2013-08-21 | 弗·哈夫曼-拉罗切有限公司 | 作为taar1配体用于cns病症的新的2-氨基噁唑啉 |
| US8242153B2 (en) * | 2008-07-24 | 2012-08-14 | Hoffmann-La Roche Inc. | 4,5-dihydro-oxazol-2YL derivatives |
| BRPI1016190A2 (pt) * | 2009-04-30 | 2017-03-28 | Novartis Ag | compostos farmacêuticos. |
| AR077969A1 (es) | 2009-08-31 | 2011-10-05 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina comomoduladores de s1p |
| US8354441B2 (en) * | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| TWI543984B (zh) | 2010-07-09 | 2016-08-01 | 艾伯維公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| CN103224468A (zh) * | 2013-05-10 | 2013-07-31 | 范强 | 四氢唑林的合成方法 |
| ES2909709T3 (es) | 2016-05-12 | 2022-05-10 | Heptares Therapeutics Ltd | Inhibidores del receptor 2 activado por proteasa |
| WO2017210616A1 (en) * | 2016-06-02 | 2017-12-07 | Purdue Pharma L.P. | Trace amine associated receptor 1 agonists and partial agonists for pain treatment |
| TW202100526A (zh) | 2019-03-06 | 2021-01-01 | 日商第一三共股份有限公司 | 吡咯并吡唑衍生物 |
| CN110041261B (zh) * | 2019-05-24 | 2022-06-24 | 广东先强药业有限公司 | 一种盐酸萘甲唑啉的制备方法 |
| BR112022001659A2 (pt) * | 2019-07-30 | 2022-03-22 | Cellix Bio Private Ltd | Compostos e composições farmacêuticas |
| IL292547A (en) | 2019-10-31 | 2022-06-01 | Escape Bio Inc | Solid forms of s1p–receptor modulator |
| CN110922361B (zh) * | 2019-11-21 | 2021-01-08 | 武汉大安制药有限公司 | 一种依托咪酯氧化杂质及其制备方法 |
| AU2021334327A1 (en) * | 2020-08-27 | 2023-05-04 | Curasen Therapeutics, Inc. | α1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE |
| CN113754524B (zh) * | 2021-09-26 | 2023-08-22 | 济源市恒顺新材料有限公司 | 一种间氟苯甲醛生产制造方法 |
| EP4499070A1 (en) * | 2022-03-24 | 2025-02-05 | Curasen Therapeutics, Inc. | Alpha 1a-adrenergic receptor agonists and methods of use |
| CN115784996A (zh) * | 2023-02-13 | 2023-03-14 | 南京海鲸药业股份有限公司 | 一种盐酸羟甲唑啉的合成方法及其应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR6551E (fr) | 1905-07-27 | 1906-12-17 | Carlo Chiesa | Séchoir à tambour rotatif, démontable et transportable, et fonctionnant à ciel ouvert, pour cocons, céréales, etc. |
| US2161938A (en) * | 1934-07-31 | 1939-06-13 | Soc Of Chemical Ind | Imidazolines |
| US2457047A (en) * | 1946-02-13 | 1948-12-21 | Monsanto Chemicals | 2-(2'-thenyl)-4, 5-dihydroimidazoles and process for making the same |
| US2778836A (en) * | 1954-04-02 | 1957-01-22 | Union Chimique Belge Sa | Substituted 2-methyl-delta2 imidazolines |
| US2744909A (en) * | 1955-06-27 | 1956-05-08 | Bristol Lab Inc | 2-(ortho-phenylbenzyl) imidazoline and acid addition salts |
| US2744910A (en) * | 1955-06-27 | 1956-05-08 | Bristol Lab Inc | 2-(ortho-benzylbenzyl)-imidazoline and acid addition salts |
| US2919274A (en) * | 1957-09-17 | 1959-12-29 | Sahyun Melville | Amidines |
| DE1121054B (de) * | 1960-11-23 | 1962-01-04 | Merck Ag E | Verfahren zur Herstellung eines neuen Imidazolinderivates und dessen Saeureadditionssalzen |
| ES323985A1 (es) * | 1966-02-26 | 1966-12-16 | Blade Pique Juan | Procedimiento para la obtenciën de derivados del imidazol |
| DE1617618B2 (de) * | 1966-06-18 | 1976-05-20 | Merck Patent Gmbh, 6100 Darmstadt | Schleimhautabschwellende mittel zur lokalen applikation |
| US3377247A (en) * | 1967-04-28 | 1968-04-09 | Dow Chemical Co | Antidepressant method |
| US3586695A (en) * | 1968-01-26 | 1971-06-22 | Dow Chemical Co | Substituted imidazolinyl indoles |
| US3660423A (en) * | 1970-02-13 | 1972-05-02 | Dow Chemical Co | 2-(substituted benzyl)methyl-2-imidazolines |
| GB1333471A (en) | 1971-01-27 | 1973-10-10 | Labaz | Imidazoline derivatives and process for preparing the same |
| GB1538097A (en) * | 1976-01-26 | 1979-01-10 | Lafon Labor | Substituted phenyl-amidines |
| US4540705A (en) * | 1983-03-14 | 1985-09-10 | Sterling Drug Inc. | Antidepressant imidazolines and related compounds |
| US4665095A (en) * | 1985-12-11 | 1987-05-12 | Abbott Laboratories | Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion |
| CS261294B1 (cs) * | 1987-07-17 | 1989-01-12 | Miroslav Protiva | 2-(2-(Fenylthio)benzyl)-2-imidazolin a jeho oxalát |
| US5969137A (en) * | 1996-09-19 | 1999-10-19 | Virginia Commonwealth University | Benzylamidine derivatives with serotonin receptor binding activity |
| CA2232467A1 (en) * | 1997-03-20 | 1998-09-20 | Richard A. Glennon | Imidazoles with serotonin receptor binding activity |
| CA2315226A1 (en) * | 1997-12-19 | 1999-07-01 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
| ES2150378B1 (es) * | 1998-08-07 | 2001-07-01 | Esteve Labor Dr | Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p. |
| CA2246027A1 (en) * | 1998-08-27 | 2000-02-27 | Virginia Commonwealth University | Benzylamidine derivatives with serotonin receptor binding activity |
| US6455734B1 (en) | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| AR024077A1 (es) * | 1999-05-25 | 2002-09-04 | Smithkline Beecham Corp | Compuestos antibacterianos |
| JP2001302643A (ja) * | 2000-04-21 | 2001-10-31 | Suntory Ltd | 環状アミジン化合物 |
| AU2001292617A1 (en) * | 2000-09-12 | 2002-03-26 | Oregon Health And Science University | Mammalian receptor genes and uses |
| CN101374832B (zh) | 2006-01-27 | 2013-03-06 | 弗·哈夫曼-拉罗切有限公司 | 4-咪唑衍生物用于cns病症的用途 |
| CA2637261A1 (en) | 2006-01-27 | 2007-08-02 | F. Hoffmann-La Roche Ag | Use of 2-imidazoles for the treatment of cns disorders |
-
2007
- 2007-01-17 BR BRPI0707315-1A patent/BRPI0707315A2/pt not_active IP Right Cessation
- 2007-01-17 EP EP07703941A patent/EP1981497A2/en not_active Withdrawn
- 2007-01-17 KR KR1020087018347A patent/KR20080080410A/ko not_active Ceased
- 2007-01-17 CN CNA2007800034858A patent/CN101374516A/zh active Pending
- 2007-01-17 CA CA002637312A patent/CA2637312A1/en not_active Abandoned
- 2007-01-17 JP JP2008551760A patent/JP2009524617A/ja active Pending
- 2007-01-17 WO PCT/EP2007/050443 patent/WO2007085557A2/en active Application Filing
- 2007-01-17 RU RU2008130455/04A patent/RU2008130455A/ru not_active Application Discontinuation
- 2007-01-17 AU AU2007209381A patent/AU2007209381A1/en not_active Abandoned
- 2007-01-19 US US11/655,468 patent/US7875645B2/en not_active Expired - Fee Related
- 2007-01-25 TW TW096102846A patent/TW200738233A/zh unknown
- 2007-01-25 AR ARP070100322A patent/AR059183A1/es not_active Application Discontinuation
-
2008
- 2008-07-17 IL IL192884A patent/IL192884A0/en unknown
- 2008-07-24 ZA ZA200806456A patent/ZA200806456B/xx unknown
- 2008-08-01 NO NO20083369A patent/NO20083369L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2008130455A (ru) | 2010-03-10 |
| AU2007209381A1 (en) | 2007-08-02 |
| WO2007085557A3 (en) | 2007-09-20 |
| CA2637312A1 (en) | 2007-08-02 |
| JP2009524617A (ja) | 2009-07-02 |
| KR20080080410A (ko) | 2008-09-03 |
| US7875645B2 (en) | 2011-01-25 |
| EP1981497A2 (en) | 2008-10-22 |
| NO20083369L (no) | 2008-10-24 |
| ZA200806456B (en) | 2009-11-25 |
| US20070197621A1 (en) | 2007-08-23 |
| BRPI0707315A2 (pt) | 2011-05-03 |
| CN101374516A (zh) | 2009-02-25 |
| TW200738233A (en) | 2007-10-16 |
| WO2007085557A2 (en) | 2007-08-02 |
| IL192884A0 (en) | 2009-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059183A1 (es) | Uso de derivados de 2- imidazol o imidazolina sustituidos para preparar medicamentos | |
| AR059206A1 (es) | Uso de derivados de 4-imidazol para trastornos del snc | |
| AR065128A1 (es) | Derivados de 2-aminooxazolinas como ligandos taar1. procesos de obtencion, composiciones farmaceuticas y usos | |
| AR067772A1 (es) | Derivados piperazinicos de nicotinamida, medicamentos que los contienen, proceso para prepararlos y usos de los mismos para el tratamiento de trastornos asociados al sistema nervioso, cardiovascular y/o trastornos metabolicos. | |
| JP2002523491A5 (es) | ||
| AR063326A1 (es) | Aminometil-2-imidazoles, medicamentos que los contienen, metodo de preparacion, y usos para el tratamiento de trastornos asociados al sistema nervioso central | |
| AR063327A1 (es) | Aminometil-4-imidazoles. procesos de obtencion y composiciones farmaceuticas | |
| BR112013024312A2 (pt) | derivados de amina heterocíclica | |
| EA200800430A1 (ru) | Замещённые тетрагидро-1н-пиридо[4,3,b] индолы как агонисты и антагонисты серотониновых рецепторов | |
| JP2004517852A5 (es) | ||
| NO20075623L (no) | Benzodioksan- og benzodioksolanderivater og deres anvendelse | |
| JP2002523508A5 (es) | ||
| CL2008002052A1 (es) | Compuestos derivados de pirazol, inhibidores de la 11 beta-hidroxi-esteroide-deshidrogenasa; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y uso para la preparacion de medicamentos para el tratamiento de diabetes, obesidad, trastornos de ingestion de comida o dislipidemia | |
| AR059207A1 (es) | Uso de derivados de 2-imidazol para el tratamiento de trastornos del snc | |
| CN101715449A (zh) | 杂环化合物及其使用方法 | |
| BR112013030698A2 (pt) | derivados de benzamida substituídas | |
| AR072876A1 (es) | Derivados de 4,5-dihidro-oxazol-2-ilo , medicamentos que los contienen, metodo de preparacion y uso de los mismos para el tratamiento de enfermedades del sistema nervioso, entre otras. | |
| MX2010009643A (es) | Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a). | |
| MX2009005509A (es) | 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a). | |
| AR075229A1 (es) | Derivados de dihidroquinolinona. | |
| TW200817383A (en) | Novel chromene and thiochromene carboxamide derivatives, methods for preparing same and therapeutic applications of same | |
| NO20073248L (no) | Derivater av isotiazol-3(2H)-on 1,1-dioksider som lever X reseptor modulatorer | |
| BR112015004511A2 (pt) | derivados de pirazol carboxamida como moduladores de taar para uso no tratamento de diversas desordens, tais como depressão, diabetes e doença de parkinson | |
| MX2010009403A (es) | Derivados de 2-aminoquinolina. | |
| MX2009005541A (es) | Indoles que actuan como antagonistas del receptor v1a. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |